MENLO PARK, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a ...

Another promising candidate, ORKA-002, which targets IL-17A/F ... potential to offer best-in-class treatments in the psoriasis field. Successful go-public transaction, raising over $475 million ...

(RTTNews) - Oruka Therapeutics, Inc. (ORKA), Friday announced the preclinical data for ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F. The findings, presented at the ...